October 19, 2012, Cambridge, MA – IntelligentMDx (IMDx) will present development and performance data of 4 high-throughput, automated, molecular diagnostic tests, targeting C. difficile, Vancomycin-resistant enterococci, Herpes Simplex viruses 1 & 2, and Influenza A/B and RSV at the Association for Molecular Pathology (AMP) 2012 Annual Meeting being held in Long Beach, CA, October 24 – 27, 2012. The AMP meeting is an opportunity for experts from a variety of clinical, laboratory, and medical fields to engage in robust discussions surrounding diagnostic, prognostic, and therapeutic approaches in molecular pathology with a shared goal of improving patient care.
The IMDx presentations will be featured in the Infectious Disease category, highlighting the unique design, development, and performance of the 4 infectious disease assays: the CE-marked IMDx C. difficile for Abbott m2000, IMDx VanR for Abbott m2000, and IMDx HSV-1/2 for Abbott m2000 assays, and the IMDx Flu A/B and RSV for Abbott m2000 assay which is anticipated to receive CE-marking in 2013.
To view the IMDx presentations at AMP, please visit:
Friday, October 26, 2012, 2:30 – 3:30 pm
Poster Slot ID02 – “Design, Development, and Performance of the IMDx Flu A/B and RSV for Abbott m2000 assay”
Poster Slot ID66 – “Development of a Fully Automated, CE-Marked Molecular Assay for the Detection of Toxigenic and Hypervirulent Strains of C. difficile”
Saturday, Oct 27, 9:45 – 10:45 am
Poster Slot ID105 – “Design, Development, and Performance Characteristics of the CE-marked IMDx VanR for Abbott m2000 assay”
Poster Slot ID109 – “Design and Development of a fully automated assay for detection and differentiation of HSV-1 and HSV-2: The IMDx HSV-1/2 for Abbott m2000”
*These products are not available for sale in the U.S. or Canada.
Based in Cambridge, MA, USA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.